prognostic factor analysis

You have access
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han and Kai Li

Cancer Biology & Medicine November 2018, 15 (4) 443-451; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0158

Main menu